Company Filing History:
Years Active: 2008-2025
Title: The Innovations of Wan-Jen Hong
Introduction
Wan-Jen Hong is a prominent inventor based in Palo Alto, CA. He has made significant contributions to the field of biomedical research, particularly in the development of therapeutic agents. With a total of 2 patents, his work focuses on innovative solutions for cancer treatment and patient safety.
Latest Patents
Wan-Jen Hong's latest patents include groundbreaking technologies. The first patent is for therapeutic antigen binding proteins specific for CD93 and methods of use thereof. This patent provides antigen binding domain polypeptides (ABD) that can be formatted as antibodies or chimeric antigen receptors. T cells that incorporate an anti-CD93 CAR are particularly useful in treating cancer, including hematologic malignancies. The second patent involves methods and compositions for determining the risk of treatment toxicity. This patent outlines methods for assessing whether a patient treated with an anti-proliferative agent is susceptible to toxicity. By obtaining an expression profile for the transcriptional response to therapy and comparing it to a reference profile, healthcare providers can better understand patient susceptibility to adverse effects.
Career Highlights
Wan-Jen Hong is affiliated with Leland Stanford Junior University, where he continues to advance his research and innovations. His work has garnered attention for its potential impact on cancer therapies and patient care.
Collaborations
Wan-Jen collaborates with esteemed colleagues, including Gilbert Chu and Virginia Goss Tusher, who contribute to his research endeavors.
Conclusion
Wan-Jen Hong's contributions to the field of biomedical research exemplify the importance of innovation in developing effective cancer treatments and improving patient safety. His patents reflect a commitment to advancing medical science and enhancing therapeutic strategies.